1. Home
  2. JHS vs CYBN Comparison

JHS vs CYBN Comparison

Compare JHS & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JHS
  • CYBN
  • Stock Information
  • Founded
  • JHS 1973
  • CYBN 2019
  • Country
  • JHS United States
  • CYBN Canada
  • Employees
  • JHS N/A
  • CYBN N/A
  • Industry
  • JHS Finance Companies
  • CYBN Pharmaceuticals and Biotechnology
  • Sector
  • JHS Finance
  • CYBN Health Care
  • Exchange
  • JHS Nasdaq
  • CYBN Nasdaq
  • Market Cap
  • JHS 131.4M
  • CYBN 147.4M
  • IPO Year
  • JHS N/A
  • CYBN N/A
  • Fundamental
  • Price
  • JHS $11.56
  • CYBN $7.26
  • Analyst Decision
  • JHS
  • CYBN Strong Buy
  • Analyst Count
  • JHS 0
  • CYBN 3
  • Target Price
  • JHS N/A
  • CYBN $85.00
  • AVG Volume (30 Days)
  • JHS 32.8K
  • CYBN 988.4K
  • Earning Date
  • JHS 01-01-0001
  • CYBN 11-12-2025
  • Dividend Yield
  • JHS 3.96%
  • CYBN N/A
  • EPS Growth
  • JHS N/A
  • CYBN N/A
  • EPS
  • JHS 0.02
  • CYBN N/A
  • Revenue
  • JHS N/A
  • CYBN N/A
  • Revenue This Year
  • JHS N/A
  • CYBN N/A
  • Revenue Next Year
  • JHS N/A
  • CYBN N/A
  • P/E Ratio
  • JHS $553.50
  • CYBN N/A
  • Revenue Growth
  • JHS N/A
  • CYBN N/A
  • 52 Week Low
  • JHS $9.76
  • CYBN $4.81
  • 52 Week High
  • JHS $11.25
  • CYBN $13.88
  • Technical
  • Relative Strength Index (RSI)
  • JHS 36.79
  • CYBN 62.87
  • Support Level
  • JHS $11.54
  • CYBN $6.86
  • Resistance Level
  • JHS $11.93
  • CYBN $8.00
  • Average True Range (ATR)
  • JHS 0.14
  • CYBN 0.41
  • MACD
  • JHS -0.04
  • CYBN 0.16
  • Stochastic Oscillator
  • JHS 1.72
  • CYBN 66.16

About JHS John Hancock Income Securities Trust

John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Share on Social Networks: